Your browser doesn't support javascript.
loading
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.
Nishimura, Tadashi; Fujimoto, Hajime; Fujiwara, Takumi; Ito, Kentaro; Fujiwara, Atsushi; Yuda, Hisamichi; Itani, Hidetoshi; Naito, Masahiro; Kodama, Shuji; Yagi, Akihiko; D'Alessandro, Valeria Fridman; Yasuma, Taro; Furuhashi, Kazuki; Saiki, Haruko; Okano, Tomohito; Tomaru, Atsushi; Tanigawa, Motoaki; D'Alessandro-Gabazza, Corina N; Gabazza, Esteban C; Yoshida, Masamichi; Hataji, Osamu; Ibata, Hidenori; Kobayashi, Tetsu.
Afiliación
  • Nishimura T; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu 514-1101, Mie, Japan.
  • Fujimoto H; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Fujiwara T; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Ito K; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Fujiwara A; Department of Genomic Medicine, Mie University Hospital, Tsu 514-8507, Mie, Japan.
  • Yuda H; Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-8544, Mie, Japan.
  • Itani H; Department of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Mie, Japan.
  • Naito M; Department of Pulmonary Medicine, Kuwana City Medical Center, Kuwana 511-0061, Mie, Japan.
  • Kodama S; Department of Respiratory Medicine, Ise Red Cross Hospital, Ise 516-8512, Mie, Japan.
  • Yagi A; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu 514-1101, Mie, Japan.
  • D'Alessandro VF; Department of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Mie, Japan.
  • Yasuma T; Department of Pulmonary Medicine, Kuwana City Medical Center, Kuwana 511-0061, Mie, Japan.
  • Furuhashi K; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Saiki H; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Okano T; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Tomaru A; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Tanigawa M; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • D'Alessandro-Gabazza CN; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Gabazza EC; Department of Respiratory Medicine, Ise Red Cross Hospital, Ise 516-8512, Mie, Japan.
  • Yoshida M; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Hataji O; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
  • Ibata H; Department of Pulmonary Medicine, Mie Prefectural General Medical Center, Yokkaichi 510-8561, Mie, Japan.
  • Kobayashi T; Respiratory Center, Matsusaka Municipal Hospital, Matsusaka 515-8544, Mie, Japan.
Cancers (Basel) ; 14(16)2022 Aug 16.
Article en En | MEDLINE | ID: mdl-36010946
Adding an immune checkpoint inhibitor to chemotherapy to treat extensive-stage small cell lung cancer is effective. However, there are no reports of an effective second-line treatment in patients previously treated with chemotherapy and immune checkpoint inhibitors as a first-line treatment. Here, we assessed the efficacy and safety of amrubicin as a second-line treatment for extensive-stage small cell lung cancer after chemotherapy and immune checkpoint inhibitor combination therapy. The study enrolled 150 patients with extensive-stage small cell lung cancer. The efficacy and the incidence of adverse events were compared between patients previously treated with immune checkpoint inhibitors and patients without previous immune checkpoint inhibitor treatment. One hundred and twenty-three patients were eligible. There was no difference in objective response rate, time-to-treatment failure, progression-free survival, and overall survival between both groups. The incidence of adverse events was similar in both treatment groups. Pretreatment with immune checkpoint inhibitors was not associated with an increase in amrubicin-related adverse events. This study shows that the efficacy of amrubicin in extensive-stage small cell lung cancer remains unchanged irrespective of previous treatment with immune checkpoint inhibitors. Amrubicin-related adverse events did not increase in patients previously treated with immune checkpoint inhibitors.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza